{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:06:48Z","timestamp":1791410808846,"version":"4.3.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12325-025-03160-4","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T05:42:04Z","timestamp":1743745324000},"page":"2465-2479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evinacumab for Homozygous Familial Hypercholesterolemia: The Italian Cohort of the ELIPSE HoFH Study"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct03399786","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Gabriella","family":"Iannuzzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Calcaterra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Stanzione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"De Ruberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Donata","family":"Di Taranto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Fortunato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Di Minno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"issue":"25","key":"3160_CR1","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","volume":"44","author":"M Cuchel","year":"2023","unstructured":"Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, et al. 2023 update on European Atherosclerosis Society Consensus Statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44(25):2277\u201391.","journal-title":"Eur Heart J"},{"issue":"32","key":"3160_CR2","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al. Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146\u201357.","journal-title":"Eur Heart J"},{"issue":"7","key":"3160_CR3","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/14712598.2022.2090242","volume":"22","author":"A Pirillo","year":"2022","unstructured":"Pirillo A, Catapano AL. Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia. Expert Opin Biol Ther. 2022;22(7):813\u201320.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"3160_CR4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/MOL.0000000000000179","volume":"26","author":"B Sjouke","year":"2015","unstructured":"Sjouke B, Hovingh GK, Kastelein JJ, Stefanutti C. Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives. Curr Opin Lipidol. 2015;26(3):200\u20139.","journal-title":"Curr Opin Lipidol"},{"issue":"22","key":"3160_CR5","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","volume":"132","author":"SS Gidding","year":"2015","unstructured":"Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132(22):2167\u201392.","journal-title":"Circulation"},{"issue":"2","key":"3160_CR6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","volume":"223","author":"FJ Raal","year":"2012","unstructured":"Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223(2):262\u20138.","journal-title":"Atherosclerosis"},{"issue":"8856","key":"3160_CR7","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/0140-6736(93)90815-X","volume":"341","author":"S Moorjani","year":"1993","unstructured":"Moorjani S, Roy M, Torres A, Betard C, Gagne C, Lambert M, et al. Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia. Lancet. 1993;341(8856):1303\u20136.","journal-title":"Lancet"},{"issue":"5","key":"3160_CR8","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/eurjpc\/zwab224","volume":"29","author":"AI Kramer","year":"2022","unstructured":"Kramer AI, Akioyamen LE, Lee S, Belanger A, Ruel I, Hales L, et al. Major adverse cardiovascular events in homozygous familial hypercholesterolaemia: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29(5):817\u201328.","journal-title":"Eur J Prev Cardiol"},{"issue":"10326","key":"3160_CR9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","volume":"399","author":"TR Tromp","year":"2022","unstructured":"Tromp TR, Hartgers ML, Hovingh GK, Vallejo-Vaz AJ, Ray KK, Soran H, et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet. 2022;399(10326):719\u201328.","journal-title":"Lancet"},{"issue":"6","key":"3160_CR10","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/MOL.0000000000000853","volume":"33","author":"TR Tromp","year":"2022","unstructured":"Tromp TR, Cuchel M. New algorithms for treating homozygous familial hypercholesterolemia. Curr Opin Lipidol. 2022;33(6):326\u201335.","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"3160_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"25","key":"3160_CR12","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013143.","journal-title":"Circulation"},{"key":"3160_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2018.06.859","volume":"277","author":"FJ Raal","year":"2018","unstructured":"Raal FJ, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: guidelines and new therapies. Atherosclerosis. 2018;277:483\u201392.","journal-title":"Atherosclerosis"},{"issue":"3","key":"3160_CR14","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1161\/CIRCRESAHA.118.313238","volume":"124","author":"RS Rosenson","year":"2019","unstructured":"Rosenson RS, Hegele RA, Koenig W. Cholesterol-lowering agents. Circ Res. 2019;124(3):364\u201385.","journal-title":"Circ Res"},{"issue":"9","key":"3160_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.029175","volume":"12","author":"M Cuchel","year":"2023","unstructured":"Cuchel M, Lee PC, Hudgins LC, Duell PB, Ahmad Z, Baum SJ, et al. Contemporary homozygous familial hypercholesterolemia in the United States: insights from the CASCADE FH Registry. J Am Heart Assoc. 2023;12(9): e029175.","journal-title":"J Am Heart Assoc"},{"key":"3160_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2020.08.027","volume":"312","author":"S Bertolini","year":"2020","unstructured":"Bertolini S, Calandra S, Arca M, Averna M, Catapano AL, Tarugi P, et al. Homozygous familial hypercholesterolemia in Italy: clinical and molecular features. Atherosclerosis. 2020;312:72\u20138.","journal-title":"Atherosclerosis"},{"issue":"12","key":"3160_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11883-021-00972-x","volume":"23","author":"A Pirillo","year":"2021","unstructured":"Pirillo A, Catapano AL, Norata GD. Monoclonal antibodies in the management of familial hypercholesterolemia: focus on PCSK9 and ANGPTL3 inhibitors. Curr Atheroscler Rep. 2021;23(12):79.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"3160_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1538\/expanim.55.27","volume":"55","author":"K Fujimoto","year":"2006","unstructured":"Fujimoto K, Koishi R, Shimizugawa T, Ando Y. Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity. Exp Anim. 2006;55(1):27\u201334.","journal-title":"Exp Anim"},{"issue":"11","key":"3160_CR19","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1210\/en.2005-0476","volume":"146","author":"A K\u00f6ster","year":"2005","unstructured":"K\u00f6ster A, Chao YB, Mosior M, Ford A, Gonzalez-DeWhitt PA, Hale JE, et al. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology. 2005;146(11):4943\u201350.","journal-title":"Endocrinology"},{"issue":"2","key":"3160_CR20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1161\/01.ATV.0000252827.51626.89","volume":"27","author":"M Shimamura","year":"2007","unstructured":"Shimamura M, Matsuda M, Yasumo H, Okazaki M, Fujimoto K, Kono K, et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler Thromb Vasc Biol. 2007;27(2):366\u201372.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"31","key":"3160_CR21","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.2174\/1381612824666181009100517","volume":"24","author":"VG Athyros","year":"2018","unstructured":"Athyros VG, Katsiki N, Dimakopoulou A, Patoulias D, Alataki S, Doumas M. Drugs that mimic the effect of gene mutations for the prevention or the treatment of atherosclerotic disease: from pcsk9 inhibition to ANGPTL3 inactivation. Curr Pharm Des. 2018;24(31):3638\u201346.","journal-title":"Curr Pharm Des"},{"issue":"3","key":"3160_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"Dewey FE, Gusarova V, Dunbar RL, O\u2019Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"16","key":"3160_CR23","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","volume":"69","author":"NO Stitziel","year":"2017","unstructured":"Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, et al. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017;69(16):2054\u201363.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"3160_CR24","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1161\/ATVBAHA.119.313051","volume":"39","author":"P Banerjee","year":"2019","unstructured":"Banerjee P, Chan KC, Tarabocchia M, Benito-Vicente A, Alves AC, Uribe KB, et al. Functional analysis of LDLR (low-density lipoprotein receptor) variants in patient lymphocytes to assess the effect of evinacumab in homozygous familial hypercholesterolemia patients with a spectrum of LDLR activity. Arterioscler Thromb Vasc Biol. 2019;39(11):2248\u201360.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"3160_CR25","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1194\/jlr.M054890","volume":"56","author":"V Gusarova","year":"2015","unstructured":"Gusarova V, Alexa CA, Wang Y, Rafique A, Kim JH, Buckler D, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res. 2015;56(7):1308\u201317.","journal-title":"J Lipid Res"},{"issue":"9","key":"3160_CR26","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s40265-021-01516-y","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A. Evinacumab: first approval. Drugs. 2021;81(9):1101\u20135.","journal-title":"Drugs"},{"key":"3160_CR27","unstructured":"U. S. Food & Drug Administration (FDA) 2021. EVKEEZA - evinacumab-dgnb injection for intravenous use. Regeneron Pharmaceuticals, Inc. Available from: https:\/\/www.acessdata.fda.gov Accessed 06 Mar 2024"},{"key":"3160_CR28","unstructured":"European Medicines Agency (EMA) 2021. Evkeeza (Evinacumab) 150 mg\/ml concentrate for solution for infusion. Ultragenyx Germany GmbH. Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/ Accessed 06 Mar 2024"},{"issue":"5","key":"3160_CR29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","volume":"149","author":"A Wiegman","year":"2024","unstructured":"Wiegman A, Greber-Platzer S, Ali S, Reijman MD, Brinton EA, Charng MJ, et al. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia. Circulation. 2024;149(5):343\u201353.","journal-title":"Circulation"},{"issue":"2","key":"3160_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/17512433.2022.2047934","volume":"15","author":"Y Gao","year":"2022","unstructured":"Gao Y, Zhang B, Yang J. Evinacumab for the treatment of homozygous familial hypercholesterolemia. Expert Rev Clin Pharmacol. 2022;15(2):139\u201345.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"3160_CR31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJMc1705994","volume":"377","author":"D Gaudet","year":"2017","unstructured":"Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med. 2017;377(3):296\u20137.","journal-title":"N Engl J Med"},{"issue":"8","key":"3160_CR32","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711\u201320.","journal-title":"N Engl J Med"},{"issue":"6","key":"3160_CR33","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","volume":"140","author":"Z Ahmad","year":"2019","unstructured":"Ahmad Z, Banerjee P, Hamon S, Chan KC, Bouzelmat A, Sasiela WJ, et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation. 2019;140(6):470\u201386.","journal-title":"Circulation"},{"issue":"5","key":"3160_CR34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40265-022-01691-6","volume":"82","author":"RA Ferraro","year":"2022","unstructured":"Ferraro RA, Leucker T, Martin SS, Banach M, Jones SR, Toth PP. Contemporary management of dyslipidemia. Drugs. 2022;82(5):559\u201376.","journal-title":"Drugs"},{"issue":"9719","key":"3160_CR35","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","volume":"375","author":"FJ Raal","year":"2010","unstructured":"Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998\u20131006.","journal-title":"Lancet"},{"issue":"1","key":"3160_CR36","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s13023-021-01999-8","volume":"16","author":"L D'Erasmo","year":"2021","unstructured":"D\u2019Erasmo L, Gallo A, Cefalu AB, Di Costanzo A, Saheb S, Giammanco A, et al. Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. Orphanet J Rare Dis. 2021;16(1):381.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3160_CR37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13023-018-0841-3","volume":"13","author":"DJ Blom","year":"2018","unstructured":"Blom DJ, Cuchel M, Ager M, Phillips H. Target achievement and cardiovascular event rates with lomitapide in homozygous familial hypercholesterolaemia. Orphanet J Rare Dis. 2018;13(1):96.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"3160_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11883-020-00858-4","volume":"22","author":"C Stefanutti","year":"2020","unstructured":"Stefanutti C. Lomitapide-a microsomal triglyceride transfer protein inhibitor for homozygous familial hypercholesterolemia. Curr Atheroscler Rep. 2020;22(8):38.","journal-title":"Curr Atheroscler Rep"},{"issue":"9860","key":"3160_CR39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","volume":"381","author":"M Cuchel","year":"2013","unstructured":"Cuchel M, Meagher EA, du Toit TH, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381(9860):40\u20136.","journal-title":"Lancet"},{"issue":"3","key":"3160_CR40","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","volume":"136","author":"DJ Blom","year":"2017","unstructured":"Blom DJ, Averna MR, Meagher EA, du Toit TH, Sirtori CR, Hegele RA, et al. Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia. Circulation. 2017;136(3):332\u20135.","journal-title":"Circulation"},{"issue":"5","key":"3160_CR41","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s12325-017-0531-x","volume":"34","author":"L D'Erasmo","year":"2017","unstructured":"D\u2019Erasmo L, Cefalu AB, Noto D, Giammanco A, Averna M, Pintus P, et al. Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in Italy. Adv Ther. 2017;34(5):1200\u201310.","journal-title":"Adv Ther"},{"issue":"5","key":"3160_CR42","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1093\/eurjpc\/zwab229","volume":"29","author":"L D'Erasmo","year":"2022","unstructured":"D\u2019Erasmo L, Steward K, Cefalu AB, Di Costanzo A, Boersma E, Bini S, et al. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. Eur J Prev Cardiol. 2022;29(5):832\u201341.","journal-title":"Eur J Prev Cardiol"},{"key":"3160_CR43","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2018.11.017","volume":"280","author":"LF Reeskamp","year":"2019","unstructured":"Reeskamp LF, Kastelein JJP, Moriarty PM, Duell PB, Catapano AL, Santos RD, et al. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2019;280:109\u201317.","journal-title":"Atherosclerosis"},{"key":"3160_CR44","unstructured":"U. S. Food & Drug Administration (FDA) 2016. KYNAMRO - mipomersen sodium injection, solution. Kastle Therapeutics Llc. Available from: https:\/\/www.acessdata.fda.gov Accessed 08 March 2024."},{"issue":"11","key":"3160_CR45","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3390\/ph15111389","volume":"15","author":"C Stefanutti","year":"2022","unstructured":"Stefanutti C, Chan DC, Di Giacomo S, Morozzi C, Watts GF. Long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia: Real-world clinical experience. Pharmaceuticals (Basel). 2022;15(11):1389.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"17","key":"3160_CR46","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1093\/eurjpc\/zwad203","volume":"30","author":"J Gu","year":"2023","unstructured":"Gu J, Kuznik A, Quon P, Chauhan A, Sravya TS, Raal FJ. Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2023;30(17):1874\u201380.","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"3160_CR47","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1080\/14779072.2021.1955349","volume":"19","author":"BA Warden","year":"2021","unstructured":"Warden BA, Duell PB. Evinacumab for treatment of familial hypercholesterolemia. Expert Rev Cardiovasc Ther. 2021;19(8):739\u201351.","journal-title":"Expert Rev Cardiovasc Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03160-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03160-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03160-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T08:02:44Z","timestamp":1744876964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03160-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3160"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03160-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gabriella Iannuzzo, Ilenia Calcaterra, Marco Gentile, Claudia Stanzione, Francesca de Ruberto, Maria Donata di Taranto, Giuliana Fortunato and Matteo Di Minno have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The protocol for ELIPSE HoFH was approved by the relevant institutional review boards or ethics committees (Federico II University Ethics Committee under number 358\/18\/ESIB8 and compassionate use by the same committee under numbers 379\/21, 380\/21, 381\/21, 382\/21, 383\/21,384\/21, 385\/21). The trial was conducted in accordance with the Declaration of Helsinki and its amendments and Good Clinical Practice guidelines. Written informed consent was obtained from each patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}